Aileron Therapeutics, Inc. (ALRN)

Market Cap	17.71M
Revenue (ttm)	n/a
Net Income (ttm)	-29.92M
Shares Out	90.82M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	343,515
Open	0.201
Previous Close	0.204
Day's Range	0.190 - 0.202
52-Week Range	0.131 - 1.080
Beta	2.27
Analysts	Buy
Price Target	2.04 (+946.2%)
Earnings Date	Nov 10, 2022

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in pa...

• Industry: Biotechnology
• IPO Date: Jun 29, 2017
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: ALRN

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ALRN stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 946.15% from the latest price.

Price Target

$2.04

(946.15% upside)

Analyst Consensus: Buy

Stock Forecasts